UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 22, 2020
 
PREMIER BIOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
 
Nevada

000-54563

27-2635666
 (State or other jurisdiction of incorporation)
 
 (Commission File Number)
 
 (I.R.S. Employer Identification No.)
 
P.O. Box 25
Jackson Center, PA 16133
 (Address of principal executive offices) (zip code)
 
 
 
 
 
 
 
 
 
 
(814) 786-8849
(Registrant’s telephone number, including area code)
 
 
 
 
 
 
 
 
 
 
 (Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company                                                        [_]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]
 


 
 
Section 5 – Corporate Governance and Management
 
Item 5.02
Departure of Directors or Certain Officers; Election of Direcdtors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
Effective on May 22, 2020, David Caplan was appointed to our Board of Directors, to serve until his successor is appointed or until our next annual meeting of shareholders. There are no arrangements or understandings between Mr. Caplan and any other person pursuant to which Mr. Caplan was selected as a director. Mr. Caplan is not anticipated to sit on any particular board committees.
 
 
                                      
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Premier Biomedical, Inc.
 
 
 
 
Dated: May 23, 2020
/s/ William Hartman
 
By:           William Hartman
 
Its: Chief Executive Officer
 

                                                 
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Premier Biomedical (PK) Charts.
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Premier Biomedical (PK) Charts.